scholarly journals Angiolymphatic invasion as a prognostic fator in resected N0 pancreatic adenocarcinoma

2017 ◽  
Vol 30 (1) ◽  
pp. 42-46
Author(s):  
Ricardo Vitor Silva de ALMEIDA ◽  
Adhemar Monteiro PACHECO-JR ◽  
Rodrigo Altenfelder SILVA ◽  
André de MORICZ ◽  
Tércio de CAMPOS
Keyword(s):  
Pancreatic Cancer ◽  
Pancreatic Adenocarcinoma ◽  
Perineural Invasion ◽  
Prognosis Factor ◽  
Curative Intent ◽  
Angiolymphatic Invasion ◽  
Digestive Cancers ◽  
Cancer Tumor ◽  
Group Survival ◽  
Hematoxylin Eosin

ABSTRACT Background: Pancreatic adenocarcinoma remains one of the worst digestive cancers. Surgical resection is the main target when treating a patient with curative intent. Aim: To assess angiolymphatic invasion as a prognostic factor in resected pN0 pancreatic cancer. Methods: Thirty-eight patients were submitted to pancreatoduodenectomy due to head pancreatic cancer. Tumor size, margins, lymph nodes, pTNM staging, angiolymphatic and perineural invasion were described in the pathologists' reports. Results: Most patients were female. Overall median survival was 13 months. Gemcitabine was the regimen of choice for chemotherapy in selected patients; however, it did not improve overall survival. pR0 resection had better survival compared with pR1. Within the pN0 group, survival was significantly better in patients without angiolymphatic invasion. Conclusion: Angiolymphatic invasion in N0 pancreatoduodenectomy can be demonstrated by the Hematoxylin-Eosin stain and may predict a poor prognosis factor for those patients.

scholarly journals Nonselective β-adrenergic blockade impacts pancreatic cancer tumor biology, decreases perineural invasion and improves patient survival

2020 ◽  
Vol 3 ◽  
pp. 8-8
Author(s):  
Alex B. Blair ◽  
Noelle R. Jurcak ◽  
Ammar Javed ◽  
Jonathan Teinor ◽  
Vincent P. Groot ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Perineural Invasion ◽  
Patient Survival ◽  
Tumor Biology ◽  
Adrenergic Blockade ◽  
Cancer Tumor

scholarly journals 345 – Non-Selective β-Adrenergic Blockade Impacts Pancreatic Cancer Tumor Biology, Decreases Perineural Invasion and Improves Patient Survival

2019 ◽  
Vol 156 (6) ◽  
pp. S-1394
Author(s):  
Alex Blair ◽  
Noelle Jurcak ◽  
Ammar A. Javed ◽  
Jonathan Teinor ◽  
Noah Rozich ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Perineural Invasion ◽  
Patient Survival ◽  
Tumor Biology ◽  
Adrenergic Blockade ◽  
Cancer Tumor

Pancreatic cancer tumor analysis in CT images using patch-based multi-resolution convolutional neural network

2021 ◽  
Vol 68 ◽  
pp. 102652
Author(s):  
Vahid Asadpour ◽  
Rex A. Parker ◽  
Patrick R. Mayock ◽  
Samuel E. Sampson ◽  
Wansu Chen ◽  
...  
Keyword(s):  
Neural Network ◽  
Pancreatic Cancer ◽  
Convolutional Neural Network ◽  
Ct Images ◽  
Cancer Tumor

scholarly journals Poly (ADP-Ribose) Polymerase 1 Protein Expression in Normal Pancreas and Pancreatic Adenocarcinoma

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Roberto Castiglione ◽  
Aldo E. Calogero ◽  
Enzo Vicari ◽  
Giovanna Calabrini ◽  
Anna Cosentino ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pancreatic Cancer ◽  
Cell Death ◽  
Pancreatic Adenocarcinoma ◽  
Cancer Tissue ◽  
Normal Pancreas ◽  
Normal Prostate ◽  
Cytoplasmic Staining ◽  
Cancer Of The Pancreas ◽  
Parp 1

Pancreatic cancer is a most frequent cancer in Europe, and the majority of cases of cancer of the pancreas are diagnosed above the age of 65. Radical surgery is the first curative treatment of pancreatic cancer, and alternative or combined therapeutic options, in particular, consist of adjuvant or neoadjuvant chemotherapy, with or without radiotherapy. Many factors, including diet and genetics, have been implicated in the development of cancer of the pancreas. Poly (ADP-ribose) polymerase 1 (PARP-1) protein is required for translocation of the apoptosis-inducing factor (AIF) from the mitochondria to the nucleus. It is involved in programmed cell death processes. Different PARP-1 gene expression proteins have been observed in various tumors such as lung, ovarian, endometrial, skin, and glioblastoma. We evaluated the expression of PARP-1 protein in pancreatic adenocarcinoma and normal pancreas tissues by immunohistochemistry. Protein PARP-1 in the nucleus was found in all samples (normal pancreas and pancreatic adenocarcinoma tissues). No cytoplasmic staining was observed in any sample. PARP-1-positive cells resulted higher in the normal pancreas compared with the pancreas with adenocarcinoma. PARP-1 overexpression in prostate cancer tissue compared with normal prostate suggests a greater activity of PARP-1 in these tumors. These findings suggest that PARP-1 expression in prostate cancer is an attempt to trigger apoptosis in this type of tumor, similarl to that reported in other cancers. This finding suggests that PARP-1-mediated cell death pathways are inhibited in this cancer.

scholarly journals An Efficient Photodynamic Therapy Treatment for Human Pancreatic Adenocarcinoma

2020 ◽  
Vol 9 (1) ◽  
pp. 192 ◽  
Author(s):  
Alexandre Quilbe ◽  
Olivier Moralès ◽  
Martha Baydoun ◽  
Abhishek Kumar ◽  
Rami Mustapha ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Photodynamic Therapy ◽  
Immune System ◽  
Cancer Cells ◽  
Pancreatic Adenocarcinoma ◽  
Cell Lines ◽  
Folate Receptor ◽  
Mice Model ◽  
Gene And Protein Expression ◽  
The Impact

To date, pancreatic adenocarcinoma (ADKP) is a devastating disease for which the incidence rate is close to the mortality rate. The survival rate has evolved only 2–5% in 45 years, highlighting the failure of current therapies. Otherwise, the use of photodynamic therapy (PDT), based on the use of an adapted photosensitizer (PS) has already proved its worth and has prompted a growing interest in the field of oncology. We have developed a new photosensitizer (PS-FOL/PS2), protected by a recently published patent (WO2019 016397-A1, 24 January 2019). This photosensitizer is associated with an addressing molecule (folic acid) targeting the folate receptor 1 (FOLR1) with a high affinity. Folate binds to FOLR1, in a specific way, expressed in 100% of ADKP or over-expressed in 30% of cases. The first objective of this study is to evaluate the effectiveness of this PS2-PDT in four ADKP cell lines: Capan-1, Capan-2, MiapaCa-2, and Panc-1. For this purpose, we first evaluated the gene and protein expression of FOLR1 on four ADKP cell lines. Subsequently, we evaluated PS2’s efficacy in our cell lines and we assessed the impact of PDT on the secretome of cancer cells and its impact on the immune system. Finally, we evaluate the PDT efficacy on a humanized SCID mouse model of pancreatic cancer. In a very interesting way, we observed a significant increase in the proliferation of activated-human PBMC when cultured with conditioned media of ADKP cancer cells subjected to PDT. Furthermore, to evaluate in vivo the impact of this new PS, we analyzed the tumor growth in a humanized SCID mice model of pancreatic cancer. Four conditions were tested: Untreated, mice (nontreated), mice with PS (PS2), mice subjected to illumination (Light only), and mice subjected to illumination in the presence of PS (PDT). We noticed that the mice subjected to PDT presented a strong decrease in the growth of the tumor over time after illumination. Our investigations have not only suggested that PS2-PDT is an effective therapy in the treatment of PDAC but also that it activates the immune system and could be considered as a real adjuvant for anti-cancer vaccination. Thus, this new study provides new treatment options for patients in a therapeutic impasse and will provide a new arsenal in the fight against PDAC.

Role of Tumor Microenvironment on Gene Expression in Pancreatic Cancer Tumor Models

2011 ◽  
Vol 171 (1) ◽  
pp. 136-142 ◽  
Author(s):  
Soeren Torge Mees ◽  
Wolf Arif Mardin ◽  
Christina Schleicher ◽  
Mario Colombo-Benkmann ◽  
Norbert Senninger ◽  
...  
Keyword(s):  
Gene Expression ◽  
Pancreatic Cancer ◽  
Tumor Microenvironment ◽  
Tumor Models ◽  
Cancer Tumor

scholarly journals Establishing an immunocompromised porcine model of human cancer for novel therapy development with pancreatic adenocarcinoma and irreversible electroporation

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Alissa Hendricks-Wenger ◽  
Kenneth N. Aycock ◽  
Margaret A. Nagai-Singer ◽  
Sheryl Coutermarsh-Ott ◽  
Melvin F. Lorenzo ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Electrical Properties ◽  
Pancreatic Adenocarcinoma ◽  
Mouse Models ◽  
Tumor Tissue ◽  
Irreversible Electroporation ◽  
Human Pancreatic Cancer ◽  
Large Animal Model ◽  
Preclinical Model ◽  
Large Animal

AbstractNew therapies to treat pancreatic cancer are direly needed. However, efficacious interventions lack a strong preclinical model that can recapitulate patients’ anatomy and physiology. Likewise, the availability of human primary malignant tissue for ex vivo studies is limited. These are significant limitations in the biomedical device field. We have developed RAG2/IL2RG deficient pigs using CRISPR/Cas9 as a large animal model with the novel application of cancer xenograft studies of human pancreatic adenocarcinoma. In this proof-of-concept study, these pigs were successfully generated using on-demand genetic modifications in embryos, circumventing the need for breeding and husbandry. Human Panc01 cells injected subcutaneously into the ears of RAG2/IL2RG deficient pigs demonstrated 100% engraftment with growth rates similar to those typically observed in mouse models. Histopathology revealed no immune cell infiltration and tumor morphology was highly consistent with the mouse models. The electrical properties and response to irreversible electroporation of the tumor tissue were found to be similar to excised human pancreatic cancer tumors. The ample tumor tissue produced enabled improved accuracy and modeling of the electrical properties of tumor tissue. Together, this suggests that this model will be useful and capable of bridging the gap of translating therapies from the bench to clinical application.

The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection

Surgery Today ◽  
1999 ◽  
Vol 29 (1) ◽  
pp. 16-22 ◽  
Author(s):  
Hideo Ozaki ◽  
Takehisa Hiraoka ◽  
Ryuji Mizumoto ◽  
Seiki Matsuno ◽  
Yoshiro Matsumoto ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Curative Resection ◽  
Perineural Invasion ◽  
Prognostic Significance ◽  
Node Metastasis

The timing and the dose of advanced care planning in patients with resectable pancreatic cancer: Who makes the call?

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 397-397 ◽  
Author(s):  
Lyudmyla Demyan ◽  
Grace Wu ◽  
Dina Moumin ◽  
Gary B Deutsch ◽  
William Nealon ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Median Number ◽  
Ductal Adenocarcinoma ◽  
Care Planning ◽  
Theory Approach ◽  
Advanced Care Planning ◽  
Curative Intent ◽  
Convenience Sample ◽  
Potential Benefits ◽  
Preoperative Counseling

397 Background:The timing and the extent of Advanced Care Planning (ACP) in patients with pancreatic ductal adenocarcinoma (PDAC) undergoing curative-intent resection are generally dictated by the surgeon performing the operation. The aim of this study is to evaluate surgeons’ insights, perceptions, and biases regarding preoperative ACP. We hypothesize that many surgeons harbor significant reservations about extensive preoperative ACP. Methods:A qualitative investigation using 1:1 interviews with 40 open-ended questions were conducted with convenience sample. Data accrual continued until theme saturation was achieved. Grounded theory approach was used for data coding and analysis. Results:A total of 10 interviews were conducted with expert pancreatic surgeons from 6 medical centers—6 males and 4 females. The median number of years in practice was 15 (IQR 13-30) and the median number of pancreatic cancer cases performed per year was 52 (IQR 39-75). During preoperative counseling all surgeons discuss the possibility of recurrence and postoperative complications but attempt to motivate patients by emphasizing hope, optimism, and fact that surgery offers the only opportunity for cure. 90% of surgeons report no formal training in ACP. All surgeons report comfort with end of life conversations when death is imminent, but most lack experience with in-depth preoperative ACP. All surgeons emphasized that ACP should be led by a physician that both knows the patient well and understands the complexity of PDAC management. All surgeons recognized potential benefits of ACP, including delivery of goal-concordant care (60%), increased prognostic awareness (40%), and better life planning (40%). 50% report discussing in-depth ACP related to perioperative complications, but not long-term oncologic outcome. 80% of surgeons report that they actively steer away from in-depth ACP during preoperative counseling. Barriers to in-depth ACP reported by surgeons include taking away hope (70%), lack of time (50%) and concern for sending “mixed messages” (50%). Further, 50% of surgeons perceived that extensive preoperative ACP is not appropriate for patients with PDAC undergoing curative-intent resection. Most surgeons (60%) believe that ACP should occur as a process throughout the disease and in-depth discussions were more appropriate during postoperative visits (30%) and/or recurrence (60%). Conclusions:Despite recognizing potential benefits, most pancreatic surgeons report actively avoiding in-depth ACP conversations prior to curative-intent surgery. Surgeons had difficulty articulating the best time for ACP and felt that ACP should occur as a continuum throughout the course of treatment, with the depth of the discussion echoing the disease progression and patients’ readiness for such conversation. Future studies could evaluate patients’ perspective on the timing and the dose of ACP.

Sign in / Sign up

Export Citation Format

Share Document